3/27
09:40 am
zlab
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer [Yahoo! Financ
Neutral
Report
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer [Yahoo! Financ
3/27
09:29 am
zlab
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
Low
Report
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
3/27
07:58 am
zlab
Novocure climbs after late-stage win for lung cancer therapy [Seeking Alpha]
Low
Report
Novocure climbs after late-stage win for lung cancer therapy [Seeking Alpha]
3/13
07:22 pm
zlab
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors [Yahoo! Finance]
Medium
Report
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors [Yahoo! Finance]
3/13
07:05 pm
zlab
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
Medium
Report
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
3/6
04:10 pm
zlab
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) [Yahoo! Finance]
Medium
Report
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) [Yahoo! Finance]
3/6
04:01 pm
zlab
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
Medium
Report
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
3/6
07:30 am
zlab
Zai Lab Announces Participation in March Investor Conference
Low
Report
Zai Lab Announces Participation in March Investor Conference
3/1
10:24 am
zlab
argenx SE (NASDAQ:ARGX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
argenx SE (NASDAQ:ARGX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/29
12:33 pm
zlab
Zai Lab Limited (NASDAQ: ZLAB) had its price target lowered by analysts at Citigroup Inc. from $123.00 to $66.00. They now have a "buy" rating on the stock.
Low
Report
Zai Lab Limited (NASDAQ: ZLAB) had its price target lowered by analysts at Citigroup Inc. from $123.00 to $66.00. They now have a "buy" rating on the stock.
2/29
09:06 am
zlab
Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/29
01:03 am
zlab
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update [Yahoo! Finance]
Low
Report
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update [Yahoo! Finance]
2/27
04:49 pm
zlab
Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results [Yahoo! Finance]
2/27
04:36 pm
zlab
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates [Yahoo! Finance]
Medium
Report
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates [Yahoo! Finance]
2/27
04:05 pm
zlab
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
Medium
Report
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
2/22
07:16 am
zlab
NovoCure GAAP EPS of -$0.45 beats by $0.07, revenue of $133.78M in-line [Seeking Alpha]
Low
Report
NovoCure GAAP EPS of -$0.45 beats by $0.07, revenue of $133.78M in-line [Seeking Alpha]
2/22
07:06 am
zlab
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]
Low
Report
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]
2/1
05:53 am
zlab
Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024: From Rova-T to Tarlatamab, DLL3 Targeted Therapies Market Gains Momentum with FDA Priority Review [Yahoo! Finance]
Medium
Report
Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024: From Rova-T to Tarlatamab, DLL3 Targeted Therapies Market Gains Momentum with FDA Priority Review [Yahoo! Finance]
1/25
04:15 pm
zlab
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
Low
Report
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
1/17
07:22 am
zlab
Zai Lab Limited (NASDAQ: ZLAB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Zai Lab Limited (NASDAQ: ZLAB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
1/17
07:22 am
zlab
Zai Lab Limited (NASDAQ: ZLAB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Zai Lab Limited (NASDAQ: ZLAB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
1/10
05:27 pm
zlab
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC [Yahoo! Finance]
Medium
Report
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC [Yahoo! Finance]
1/10
05:12 pm
zlab
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
Medium
Report
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
1/8
07:12 am
zlab
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update [Yahoo! Finance]
Low
Report
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update [Yahoo! Finance]
1/8
01:06 am
zlab
argenx Highlights 2024 Strategic Priorities [Yahoo! Finance]
Low
Report
argenx Highlights 2024 Strategic Priorities [Yahoo! Finance]